BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Manolis AA, Manolis TA, Melita H, Manolis AS. Sodium-Glucose Cotransporter Type 2 Inhibitors and Cardiac Arrhythmias. Trends in Cardiovascular Medicine 2022. [DOI: 10.1016/j.tcm.2022.04.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Paolisso P, Bergamaschi L, Gragnano F, Gallinoro E, Cesaro A, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Nuccia M, Andrea OJ, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Marfella R, Calabrò P, Pizzi C, Barbato E. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry. Pharmacol Res 2023;187:106597. [PMID: 36470546 DOI: 10.1016/j.phrs.2022.106597] [Reference Citation Analysis]
2 Manolis TA, Manolis AA, Melita H, Manolis AS. Neuropsychiatric disorders in patients with heart failure: not to be ignored. Heart Fail Rev 2022. [DOI: 10.1007/s10741-022-10290-2] [Reference Citation Analysis]
3 Scheen AJ. Glucose-lowering agents and risk of ventricular arrhythmias and sudden cardiac death: a comprehensive review ranging from sulphonylureas to SGLT2 inhibitors. Diabetes & Metabolism 2022. [DOI: 10.1016/j.diabet.2022.101405] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Scheen AJ. Dissecting the reduction in cardiovascular death with SGLT2 inhibitors: Potential contribution of effects on ventricular arrhythmias and sudden cardiac death? Diabetes Epidemiology and Management 2022;8:100107. [DOI: 10.1016/j.deman.2022.100107] [Reference Citation Analysis]
5 Cesaro A, Gragnano F, Paolisso P, Bergamaschi L, Gallinoro E, Sardu C, Mileva N, Foà A, Armillotta M, Sansonetti A, Amicone S, Impellizzeri A, Esposito G, Morici N, Oreglia JA, Casella G, Mauro C, Vassilev D, Galie N, Santulli G, Pizzi C, Barbato E, Calabrò P, Marfella R. In-hospital arrhythmic burden reduction in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: Insights from the SGLT2-I AMI PROTECT study. Front Cardiovasc Med 2022;9:1012220. [PMID: 36237914 DOI: 10.3389/fcvm.2022.1012220] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
6 Scheen AJ. Antidiabetic agents and risk of atrial fibrillation/flutter: a comparative critical analysis with a focus on differences between SGLT2 inhibitors and GLP-1 receptor agonists. Diabetes & Metabolism 2022. [DOI: 10.1016/j.diabet.2022.101390] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
7 Hong T, Richmond B. A New Era of Antiarrhythmics - Perspectives from SGLT2i Therapy. Trends Cardiovasc Med 2022:S1050-1738(22)00069-X. [PMID: 35561997 DOI: 10.1016/j.tcm.2022.05.002] [Reference Citation Analysis]